Artiva Biotherapeutics (ARTV) Change in Cash (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Change in Cash for 4 consecutive years, with -$5.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Cash rose 40.34% year-over-year to -$5.7 million; the TTM figure through Mar 2026 stood at -$9.4 million (up 46.32% YoY), while the FY2025 annual figure was -$13.3 million, changed 0.47% from the prior year.
• Change in Cash slipped to -$5.7 million in Q1 2026 per ARTV's latest filing, from $1.2 million in the prior quarter.
• Across five years, Change in Cash topped out at $21.6 million in Q3 2024 and bottomed at -$15.6 million in Q4 2024.
• Historically, Change in Cash has averaged -$3.0 million across 4 years, with a median of -$5.3 million in 2024.
• On a YoY basis, Change in Cash climbed as much as 107.62% in 2025 and fell as far as 113.68% in 2025.
• Artiva Biotherapeutics' Change in Cash stood at -$12.4 million in 2023, then declined by 26.37% to -$15.6 million in 2024, then surged by 107.62% to $1.2 million in 2025, then plunged by 581.64% to -$5.7 million in 2026.
• Business Quant data shows ARTV's Change in Cash at -$5.7 million in Q1 2026, $1.2 million in Q4 2025, and -$3.0 million in Q3 2025.